|Mr. Michael A. Sherman||Chief Exec. Officer, Pres and Director||545.98k||N/A||51|
|Dr. Philip S. Low Ph.D.||Co-Founder, Chief Science Officer and Director||N/A||N/A||69|
|Ms. Katherine K. Parker||VP of HR||347.24k||N/A||52|
|Dr. Alison A. Armour M.B.,Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR||Chief Medical Officer||460.7k||N/A||53|
|Dr. Christopher P. Leamon Ph.D.||VP of R&D||449.04k||28.97k||51|
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The companys products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Endocyte, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 9.